...
首页> 外文期刊>Journal of physical chemistry letters >Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks
【24h】

Novel Coronavirus Polymerase and Nucleotidyl-Transferase Structures: Potential to Target New Outbreaks

机译:新型冠状病毒聚合酶和核苷酰转移酶结构:占靶向新爆发的潜力

获取原文
获取原文并翻译 | 示例

摘要

The pandemic outbreak of a new coronavirus (CoV), SARS-CoV-2, has captured the world's attention, demonstrating that CoVs represent a continuous global threat. As this is a highly contagious virus, it is imperative to understand RNA-dependent-RNApolymerase (RdRp), the key component in virus replication. Although the SARS-CoV-2 genome shares 80% sequence identity with severe acute respiratory syndrome SARS-CoV, their RdRps and nucleotidyl-transferases (NiRAN) share 98.1% and 93.2% identity, respectively. Sequence alignment of six coronaviruses demonstrated higher identity among their RdRps (60.9%-98.1%) and lower identity among their Spike proteins (27%-77%). Thus, a 3D structural model of RdRp, NiRAN, non-structural protein 7 (nsp7), and nsp8 of SARS-CoV-2 was generated by modeling starting from the SARS counterpart structures. Furthermore, we demonstrate the binding poses of three viral RdRp inhibitors (Galidesivir, Favipiravir, and Penciclovir), which were recently reported to have clinical significance for SARS-CoV-2. The network of interactions established by these drug molecules affirms their efficacy to inhibit viral RNA replication and provides an insight into their structure-based rational optimization for SARS-CoV-2 inhibition.
机译:新冠心病(COV)的大流行爆发,SARS-COV-2捕获了世界的关注,表明COVS代表着持续的全球威胁。由于这是一种高度传染性的病毒,因此必须了解RNA依赖性rnapolymerase(RDRP),病毒复制中的关键组分是必要的。虽然SARS-COV-2基因组共享80%的序列同一性,但重量急性呼吸综合征SARS-COV,其RDRPS和核苷酸转移酶(NIRAN)分别分别占98.1%和93.2%的同一性。六个冠状病毒的序列对准在其RDRPS(60.9%-98.1%)中具有更高的身份(60.9%-98.1%),其穗蛋白质中的较低的身份(27%-77%)。因此,通过从SARS对应结构开始,通过建模来产生RDRP,NIRAN,非结构蛋白质7(NSP7)和NSP8的3D结构模型,并产生SARS-COV-2的。此外,我们证明了三种病毒RDRP抑制剂(Galidesivir,Favipiravir和Penciclovir)的结合姿势,其最近据报道对SARS-COV-2具有临床意义。这些药物建立的相互作用网络确认了它们对抑制病毒RNA复制的功效,并对SARS-COV-2抑制的基于结构的合理优化提供了深入研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号